Pathways to patients
How a customized stem cell therapy (a 351 biologic) moves from the lab to US patients.
- Preclinical and CMC foundation. Define the product: cell source, manufacturing process, potency assay, release specifications, and safety studies (tumorigenicity, biodistribution, as relevant).
- Early FDA engagement. CBER's Office of Therapeutic Products (OTP) offers INTERACT meetings for early, informal advice, and pre-IND meetings before you file.
- Investigational New Drug application (IND). Required before any human use. Academic investigators can hold their own INDs. FDA has 30 days to respond before a study may begin.
- Clinical trials (Phase 1 to 3). FDA's 2025 draft guidances encourage innovative designs for small populations and multi-site trials that pool data to support a BLA.
- Expedited programs. Regenerative Medicine Advanced Therapy (RMAT) designation is for cell and tissue therapies intended for serious or life-threatening conditions with preliminary clinical evidence. It sits alongside Fast Track, Breakthrough Therapy, Priority Review and Accelerated Approval.
- Biologics License Application (BLA). Approval covers the product and its manufacturing process and facilities.
- Post-approval. Long-term follow-up (especially for gene-modified cells), REMS where required, and post-approval manufacturing changes.
Access before approval
| Route | Who it serves | Key condition |
|---|---|---|
| Clinical trial (IND) | Eligible enrolled patients | FDA-cleared protocol and IRB approval |
| Expanded access (single patient, intermediate-size, treatment IND) | Patients with serious conditions and no comparable alternative | FDA authorization, IRB approval and the sponsor's agreement |
| Right to Try (federal law, 2018) | Eligible patients with life-threatening conditions | Investigational product has completed Phase 1, and the manufacturer agrees |
Customized and point-of-care manufacturing
Truly individualized therapies (autologous, patient-specific or N-of-1) raise particular CMC questions: making the product at several sites, comparability between batches, and release testing on short timelines. FDA has discussed distributed and point-of-care manufacturing models publicly. Any such model still runs under an IND or a BLA, with quality controls at every site. There is no stand-alone "clinic license" route.
Tip: put manufacturing-site strategy (central, hub-and-spoke or point-of-care) on the table at your first INTERACT or pre-IND meeting. Changing it later is costly.